Company profiles


About AstraZeneca in Cardiovascular, Renal & Metabolic Diseases (CVMD).
Cardiovascular, renal and metabolic diseases together form one of AstraZeneca’s main therapy areas and platforms for future growth. By following the science to understand more clearly the underlying links between the heart, kidney and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling co-morbidities. Our ambition is to modify or halt the natural course of CVMDs and even regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and CVMD health for millions of patients worldwide.

Kenilworth, NJ 07033
Today MSD is a global healthcare leader working to help the world be well. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit and connect with us on Twitter, Facebook and YouTube.

International Medical Press 
76-78 Old Street
London EC1V 9AZ
United Kingdom 
Tel: +44 20 7398 0700
International Medical Press (IMP) specializes in providing independent and accredited medical education activities funded through unrestricted educational grants. IMP has extensive experience in medical education, is backed by enduring relationships with faculty and provides strong scientific support across several therapy areas.
IMP is a founding partner of the Good CME Practice (gCMEp) Group that is committed to delivering patient-centred, balanced and effective medical education.

Contact in Israel:
10 Beni Gaon st. Netaniya Tel: +972-9-8633700,
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care.
This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic diseases: haemophilia, growth disorders and obesity. Our ambition is to take the lead in each of these areas, driving change with an unfailing belief that it can be done.
Headquartered in Denmark, Novo Nordisk employs approximately 41,700 people in 77 countries and markets its products in more than 165 countries.

Boehringer Ingelheim Israel Ltd.
P.O.Box 4124 Hertzelia
Tel: +972-9-9730500 / +972-546677456
Contact Name: Taly Burke

Boehringer Ingelheim Israel is part of Boehringer Ingelheim group, one of the world's 20 leading pharmaceutical companies. The company's key areas of interest are: Diabetes, Respiratory, Cardiovascular, Immunology, Oncology and diseases of the central nervous system. Value through Innovation is the central concept of our corporate vision.

Eli Lilly Israel
Hasheizaf 4, Raanana
Tel: 972-9-9606234
Fax: 972-9-9576001
Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Our heritage and our values are the foundation of our promise to unite caring with discovery to make life better for people around the world.
Our mission
We make medicines that help people live longer, healthier, more active lives.
Our values
Integrity, excellence, respect for people
Our vision
We will make a significant contribution to humanity by improving global health in the 21st century.

Goush-Etzion 7, Givat Shmuel
Tel.: +972-03-9645010
Founded in Israel in 2004 by Dr. Dov Fogel, Ascarit develops proprietary nutraceutical products for metabolic diseases. Extensive research, including work on herbal extraction techniques, dry-powder conversion and safety evaluation led to AscaRx, Ascarit’s flagship product. This is a herbal-based food supplement with remarkable blood glucose and lipid regulating properties. Clinical trial results have demonstrated AscaRx’s ability to control blood sugar levels in Type 2 diabetes mellitus. Ascarit Ltd. has signed an R&D association agreement with Maccabi Health Care, an Israeli Health Services Supplier, for research and development of AscaRx in Israel.

InBody is the global leader in the body composition analysis industry with world class technological advancements. InBody would be a valuable tool for doctors so they can easily understand their overweight patients or patients with risk factors associated with diabetes. InBody technology provides accurate measures for body composition through its four core technologies. That information is then translated into useful outputs such as body fat percentage, total body water, lean body mass and visceral fat area. Visceral fat area has an important contribution to diabetics because of the association between high visceral fat levels and diabetes.

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 121,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.

Medial EarlySign’s advanced AI-based algorithm platform helps healthcare organizations accurately predict and stratify individuals at high risk for developing serious health conditions, by leveraging routine blood test results and EHR data. The company creates actionable opportunities for early intervention to delay progression of illness, improve patient outcomes, focus financial resources, and reduce overall costs. Medial EarlySign is developing a number of clinically supported AlgoMarker™ risk predictors to identify patients with a high probability for harboring or developing specific illnesses, including cancers, diabetes and other life-threatening conditions. The company’s platform has been supported by peer-reviewed research published by internationally recognized health organizations and hospitals. Founded in 2013, Medial EarlySign is headquartered in Kfar Malal, Israel.